The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice

Journal of Autoimmunity

Volumn 31, Issue 2, 2008, Pages 123-130

  Reilly, Christopher M ^a,b   Thomas, Megan ^a   Gogal Jr , Robert ^a,b   Olgun, Selen ^b   Santo, Arben ^b   Sodhi, Renna ^f   Samy, Eileen T ^c   Peng, Stanford L ^d   Gilkeson, Gary S ^e   Mishra, Nilamadhab ^f  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c Inflammation   (United States)

^d Clinical Research and Exploratory Development   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Lupus nephritis; Mouse model; NZB NZW; Treg cell

Indexed keywords

BASILIXIMAB; DIMETHYL SULFOXIDE; DOUBLE STRANDED DNA; GELATINASE B; IMMUNOGLOBULIN G; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLOMERULOPATHY; HISTOPATHOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN SIZE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD4; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; ORGAN SIZE; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 50849102708     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.04.020     Document Type: Article

References (48)

1. He H., and Lehming N. Global effects of histone modifications. Brief Funct Genomic Proteomic 2 (2003) 234-243
2. Sanderson L., Taylor G.W., Aboagye E.O., Alao J.P., Latigo J.R., Coombes R.C., et al. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. Drug Metab Dispos 32 (2004) 1132-1138
3. Shaker S., Bernstein M., Momparler L.F., and Momparler R.L. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 27 (2003) 437-444
4. Vanhaecke T., Papeleu P., Elaut G., and Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 11 (2004) 1629-1643
5. Papeleu P., Loyer P., Vanhaecke T., Elaut G., Geerts A., Guguen-Guillouzo C., et al. Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes. J Hepatol 39 (2003) 374-382
6. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
7. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 101 (2004) 3921-3926
8. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 99 (2002) 2995-3000
9. Mishra N., Brown D.R., Olorenshaw I.M., and Kammer G.M. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci U S A 98 (2001) 2628-2633
10. Bode K.A., Schroder K., Hume D.A., Ravasi T., Heeg K., Sweet M.J., et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 122 (2007) 596-606
11. Gray S.G., and Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 1 (2006) 67-75
12. +bright T cells in peripheral blood of patients with primary Sjogren's syndrome. Lupus 17 (2008) 34-39
13. Wahl S.M., and Chen W. Transforming growth factor-beta-induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Res Ther 7 (2005) 62-68
14. Wenzel J., Henze S., Brahler S., Bieber T., and Tuting T. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Exp Dermatol 14 (2005) 454-459
15. Salaman M.R. A two-step hypothesis for the appearance of autoimmune disease. Autoimmunity 36 (2003) 57-61
16. Pan H., Lu H.M., Hu W.M., Tian B.L., Liu X.B., Zhang Z.D., et al. Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation. Transplant Proc 39 (2007) 3452-3454
17. Ahmed S.A., Gogal Jr. R.M., and Walsh J.E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170 (1994) 211-224
18. Gilkeson G.S., Pippen A.M., and Pisetsky D.S. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J Clin Invest 95 (1995) 1398-1402
19. Takahashi I., Miyaji H., Yoshida T., Sato S., and Mizukami T. Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J Antibiot (Tokyo) 49 (1996) 453-457
20. Bruserud O., Stapnes C., Ersvaer E., Gjertsen B.T., and Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 8 (2007) 388-400
21. Takai N., Ueda T., Nishida M., Nasu K., and Narahara H. Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells. Int J Mol Med 21 (2008) 109-115
22. Adcock I.M. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 150 (2007) 829-831
23. Takada Y., Gillenwater A., Ichikawa H., and Aggarwal B.B. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281 (2006) 5612-5622
24. Waters S.T., McDuffie M., Bagavant H., Deshmukh U.S., Gaskin F., Jiang C., et al. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 199 (2004) 255-264
25. Waters S.T., Fu S.M., Gaskin F., Deshmukh U.S., Sung S.S., Kannapell C.C., et al. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol 100 (2001) 372-383
26. + regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 117 (2006) 280-286
27. Sfikakis P.P., Souliotis V.L., Fragiadaki K.G., Moutsopoulos H.M., Boletis J.N., and Theofilopoulos A.N. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123 (2007) 66-73
28. Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 175 (2005) 8392-8400
29. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13 (2007) 1299-1307
30. + regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum 52 (2005) 1180-1184
31. + regulatory T cells. Radiat Res 169 (2008) 59-66
32. Mishra N., Reilly C.M., Brown D.R., Ruiz P., and Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111 (2003) 539-552
33. Reilly C.M., Mishra N., Miller J.M., Joshi D., Ruiz P., Richon V.M., et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 173 (2004) 4171-4178
34. Gregg R.K., Jain R., Schoenleber S.J., Divekar R., Bell J.J., Lee H.H., et al. A sudden decline in active membrane-bound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol 173 (2004) 7308-7316
35. + regulatory T cells. J Exp Med 201 (2005) 1061-1067
36. +CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172 (2004) 5149-5153
37. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 (2003) 1875-1886
38. + regulatory T cell activity in both humans and mice. J Immunol 172 (2004) 834-842
39. Ostroukhova M., Seguin-Devaux C., Oriss T.B., Dixon-McCarthy B., Yang L., Ameredes B.T., et al. Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. J Clin Invest 114 (2004) 28-38
40. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
41. Crispin J.C., Martinez A., and Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21 (2003) 273-276
42. Butler L.M., Webb Y., Agus D.B., Higgins B., Tolentino T.R., Kutko M.C., et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 7 (2001) 962-970
43. Elaut G., Laus G., Alexandre E., Richert L., Bachellier P., Tourwe D., et al. A metabolic screening study of trichostatin A (TSA) and TSA-like histone deacetylase inhibitors in rat and human primary hepatocyte cultures. J Pharmacol Exp Ther 321 (2007) 400-408
44. Van Lint C., Emiliani S., and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5 (1996) 245-253
45. Richards H.B., Satoh M., Shaw M., Libert C., Poli V., and Reeves W.H. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 188 (1998) 985-990
46. Finck B.K., Chan B., and Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 94 (1994) 585-591
47. McMurray R.W., Hoffman R.W., Nelson W., and Walker S.E. Cytokine mRNA expression in the B/W mouse model of systemic lupus erythematosus-analyses of strain, gender, and age effects. Clin Immunol Immunopathol 84 (1997) 260-268
48. Haller D., Holt L., Kim S.C., Schwabe R.F., Sartor R.B., and Jobin C. Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. J Biol Chem 278 (2003) 23851-23860